載入中
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
前收盤價
US$1.89
+US$0.08 · +4.42%
盤中時間採用ET。市場資料可能有所延遲。
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
日內區間
目前US$1.89
52週區間
目前US$1.89
盤中時間採用ET。市場資料可能有所延遲。
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
日內區間
目前US$1.89
52週區間
目前US$1.89
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | — | 2831.2萬 USD |
| 銷貨成本 | 112.8萬 USD | 117.8萬 USD | 117萬 USD | 105.7萬 USD | 123.4萬 USD |
| 毛利 | −112.8萬 USD | −117.8萬 USD | −117萬 USD | −105.7萬 USD | 2707.8萬 USD |
| 研究與開發 | 2490.3萬 USD | 3365.6萬 USD | 2267.9萬 USD | 1704.6萬 USD | 4860.7萬 USD |
| 銷售、一般及管理費用 | 1281.1萬 USD | 1133萬 USD | 1189.6萬 USD | 563萬 USD | 1777.8萬 USD |
| 營業費用 | 3658.6萬 USD | 4380.8萬 USD | 3457.5萬 USD | 2267.6萬 USD | 6638.5萬 USD |
| 利息收入 | 77.6萬 USD | 77.7萬 USD | 37.3萬 USD | 6.48萬 USD | 3392 USD |
| 利息支出 | 113.3萬 USD | 45.5萬 USD | 105.9萬 USD | 359.58萬 USD | 87.64萬 USD |
| 折舊和攤銷 | 112.8萬 USD | 117.8萬 USD | 117萬 USD | 105.7萬 USD | 25.15萬 USD |
| 營業利益 | −3771.4萬 USD | −4498.6萬 USD | −3574.5萬 USD | −2373.3萬 USD | −3930.7萬 USD |
| 淨利 | −3957.1萬 USD | −5189.8萬 USD | −3519.5萬 USD | −2820.8萬 USD | −2640.07萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$11.83
上漲空間 525.93%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年6月2日 | 1:10 | — | — |
已生效 2023年6月2日
1:10
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI112.16萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM58.96萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF38.77萬0.00%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO21.94萬0.00%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO20.43萬0.00%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC9.07萬0.01%13.17億 USD0.60%US$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG3.8萬0.00%17億 USD0.06%US$260.49+0.91%
iShares Russell 2500 ETFSMMD1.24萬0.00%40.62億 USD0.23%US$86.29+0.38%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
